Alexion Pharmaceuticals
Offices in New Haven, Connecticut | |
| Type | Subsidiary |
|---|---|
| Nasdaq: ALXN | |
| Industry | Pharmaceutical industry |
| Founded | 1992 |
| Founder | Leonard Bell |
| Headquarters | Boston, Massachusetts, U.S. |
| Key people | Leonard Bell (chairman) Ludwig N. Hantson (CEO) |
| Products | Eculizumab (Soliris) Ravulizumab (Ultomiris) Asfotase alfa (Strensiq) Sebelipase alfa (Kanuma) Andexanet alfa (Andexxa) |
| Revenue | |
| Total assets | |
| Total equity | |
Number of employees | 2,525 (2020) |
| Parent | AstraZeneca |
| Website | www |
| Footnotes | |
Alexion Pharmaceuticals, Inc., a subsidiary of AstraZeneca, is a pharmaceutical company headquartered in New Haven, Connecticut, specializing in orphan drugs for rare diseases.
Its products include eculizumab (Soliris) and ravulizumab (Ultomiris), both used to treat the rare disorders of atypical hemolytic uremic syndrome (aHUS) and paroxysmal nocturnal hemoglobinuria (PNH); asfotase alfa (Strensiq), used to treat hypophosphatasia; sebelipase alfa (Kanuma), used to treat lysosomal acid lipase deficiency, and andexanet alfa (Andexxa), used to stop life threatening or uncontrollable bleeding in people who are taking rivaroxaban or apixaban.
With costs that can reach as much as $2 million per year, the drugs manufactured by Alexion are some of the most expensive drugs worldwide.